MiNK Therapeutics (6Q40) Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
6Q40 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
MiNK Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.55 |
| 52 Week High | US$12.70 |
| 52 Week Low | US$6.60 |
| Beta | 0.48 |
| 1 Month Change | -5.00% |
| 3 Month Change | 1.79% |
| 1 Year Change | -61.49% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 7.13% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6Q40 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.8% | 0.8% | 1.5% |
| 1Y | -61.5% | 4.6% | 0.8% |
Return vs Industry: 6Q40 underperformed the German Biotechs industry which returned 5.8% over the past year.
Return vs Market: 6Q40 underperformed the German Market which returned 0.9% over the past year.
Price Volatility
| 6Q40 volatility | |
|---|---|
| 6Q40 Average Weekly Movement | 16.1% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 6Q40's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6Q40's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 15 | Jen Buell | minktherapeutics.com |
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS). It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for autoimmune diseases, including in graft-versus-host disease prevention.
MiNK Therapeutics, Inc. Fundamentals Summary
| 6Q40 fundamental statistics | |
|---|---|
| Market cap | €46.32m |
| Earnings (TTM) | -€10.95m |
| Revenue (TTM) | n/a |
Is 6Q40 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6Q40 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$12.47m |
| Earnings | -US$12.47m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6Q40 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/28 22:37 |
| End of Day Share Price | 2026/07/28 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MiNK Therapeutics, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |
| Maneka Mirchandaney | Evercore ISI |